GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese WomenEva W. Iepsen, Signe S. Torekov, J. Lundgren et al.|The Journal of Clinical Endocrinology & Metabolism|2015Cited by 187
Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptorsM Gabe, Mette M. Rosenkilde, Mie Fabricius Pedersen et al.|Biochemical Pharmacology|2018Cited by 101
Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in Gastric Bypass SurgeryCecilia Ratner, Birgitte Holst, Louise J. Skov et al.|Endocrinology|2016Cited by 73
Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long‐term impairment of the GIP systemM Gabe, Mette M. Rosenkilde, Wijnand J. C. van der Velden et al.|Basic & Clinical Pharmacology & Toxicology|2019Cited by 53
GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in RatsWijnand J. C. van der Velden, Mette M. Rosenkilde, Florent X. Smit et al.|ACS Pharmacology & Translational Science|2021Cited by 33